Patients with disorders of the blood protein haemoglobin often depend on lifelong blood transfusions. That could change, given the success of gene therapy in a patient with one such disorder.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Anderson, W. F. Science 226, 401–409 (1984).
Cavazzana-Calvo, M. et al. Nature 467, 318–322 (2010).
Cavazzana-Calvo, M. et al. Science 288, 669–672 (2000).
Aiuti, A. et al. Science 296, 2410–2413 (2002).
Hacein-Bey-Abina, S. et al. Science 302, 415–419 (2003).
Ott, M. G. et al. Nature Med. 12, 401–409 (2006).
Montini, E. et al. Nature Biotechnol. 24, 687–696 (2006).
Cartier, N. et al. Science 326, 818–823 (2009).
Fusco, A. & Fedele, M. Nature Rev. Cancer 7, 899–910 (2007).
Inoue, N. et al. Blood 108, 4232–4236 (2006).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Persons, D. Targeting β-thalassaemia. Nature 467, 277–278 (2010). https://doi.org/10.1038/467277a
Published:
Issue Date:
DOI: https://doi.org/10.1038/467277a